Cardima(R), Inc. (Nasdaq SC: CRDM), developer of the REVELATION(R) Tx, REVELATION(R) T-Flex and REVELATION(R) Helix microcatheter systems for the treatment of atrial fibrillation (AF), today reported that it has received written notice from Nasdaq that, in accordance with Nasdaq Marketplace Rule 4310(c)(8)(D), the Company will be provided an additional 180 days, or until May 5, 2005, to regain compliance with the Nasdaq rule requiring a $1.00 minimum closing bid price for the Company’s common stock.
